spevatamig + capecitabine + oxaliplatin

Spevatamig + capecitabine + oxaliplatin is a combination regimen being studied for the treatment of advanced or metastatic gastrointestinal cancers, including gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, biliary tract carcinoma, and pancreatic ductal adenocarcinoma. Spevatamig (PT886) is a novel bispecific monoclonal antibody that targets Claudin 18.2 and CD47, thereby promoting anti-tumor immune response via blockade of CD47 ("don't eat me" signal) and selective binding to Claudin 18.2 expressing tumor cells[1][4][6]. Capecitabine is a small molecule chemotherapy prodrug that is enzymatically converted in vivo to fluorouracil, which is an antimetabolite inhibiting DNA synthesis in rapidly dividing cancer cells[7]. Oxaliplatin is a platinum-based small molecule chemotherapy agent that forms DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death in proliferating tumor cells[1].